Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
856 questions in 87 reviews · Cystic Fibrosis and Genetic Disorders
current versionsNo studies 856 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists Quality of life  · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists Number of exacerbations  · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists Participant‐reported symptom score  · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled beta‐2 agonists vs placebo Quality of life  · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists Change from baseline in FVC (% predicted) Â · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled beta‐2 agonists vs short‐acting inhaled muscarinic antagonists Sputum volume (mL) Â · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Short‐acting inhaled muscarinic antagonists vs placebo Quality of life  · children and adults with cystic fibrosis Short‐acting inhaled bronchodilators for cystic fibrosis (2022) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy Time to next course of antibiotics  · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy Adverse events during treatment · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: single vs combination intravenous anti‐pseudomonal antibiotic therapy Additional treatment required  · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: single vs combination intravenous anti‐pseudomonal antibiotic therapy Time to next course of antibiotics  · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: single vs combination intravenous anti‐pseudomonal antibiotic therapy Quality of life  · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy Change in FEV1 (% predicted) · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy Change in sputum P aeruginosa density at end of treatment (cfu/g) Â · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: Single vs combination intravenous anti‐pseudomonal antibiotic therapy Additional treatment required  · children and adults with cystic fibrosis Single versus combination intravenous anti‐pseudomonal antibiotic therapy for people with cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Dietary advice vs oral nutritional supplements Length of hospital stay (days) Â · adults with disease‐related malnutrition Dietary advice with or without oral nutritional supplements for disease‐related malnutrition in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Dietary advice vs oral nutritional supplements Complications  · adults with disease‐related malnutrition Dietary advice with or without oral nutritional supplements for disease‐related malnutrition in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Dietary advice vs oral nutritional supplements Change in fat‐free mass (kg) · adults with disease‐related malnutrition Dietary advice with or without oral nutritional supplements for disease‐related malnutrition in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Dietary advice vs no advice Number of people admitted or readmitted to hospital · adults with disease‐related malnutrition Dietary advice with or without oral nutritional supplements for disease‐related malnutrition in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Dietary advice plus supplements vs no dietary advice plus no supplements Number of people admitted or re‐admitted to hospital · adults with disease‐related malnutrition Dietary advice with or without oral nutritional supplements for disease‐related malnutrition in adults (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ withdrawal of penicillin prophylaxis vs continuation Compliance to treatment · children with SCD who have been receiving prophylactic penicillin for at least two years Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ initiation of penicillin prophylaxis vs placebo Antibiotic‐resistant organisms isolated · children with SCD Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings ‐ initiation of penicillin prophylaxis vs placebo Requirement of other courses of antibiotics · children with SCD Prophylactic antibiotics for preventing pneumococcal infection in children with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Morning vs evening inhalation of dornase alfa FEF25-75 (% predicted) · adults and children with cystic fibrosis Timing of dornase alfa inhalation for cystic fibrosis (2021) · Cochrane | no estimate extracted | NR | No studies |
Arginine butyrate plus standard care alone vs standard care alone Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Arginine butyrate plus standard care alone vs standard care alone Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Arginine butyrate plus standard care alone vs standard care alone Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs placebo Complete leg ulcer closure (defined as 100% epithelization or skin closure without drainage) ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs placebo Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs placebo Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs placebo Quality of life ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Isoxsuprine vs placebo Time to ulcer closure ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs placebo Amputation ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Propionyl‐L‐carnitine vs placebo Adverse events ‐ not measured · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
RGD peptide matrix vs placebo Time to ulcer closure ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
RGD peptide matrix vs placebo Change in size ulcers healed ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
RGD peptide matrix vs placebo Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
RGD peptide matrix vs placebo Quality of life ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
RGD peptide matrix vs placebo Amputation ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Time to closure ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Quality of life ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Solcoseryl vs antiseptic agent Amputation ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Complete leg ulcer closure ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Time to closure ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Isoxsuprine vs placebo Ulcer‐free survival following treatment for SCLU (free from leg ulcer recurrence) ‐ not reported · individuals with sickle cell disease and a leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Quality of life ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |
Duoderm® (hydroactive dressing) vs antiseptic agent Amputation ‐ not reported · individuals with sickle cell disease and leg ulcer Interventions for treating leg ulcers in people with sickle cell disease (2021) · Cochrane | no estimate extracted | NR | No studies |